🔎 Trials Near Me

Inicio › Cáncer de pulmón de células no pequeñas › Wisconsin

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Wisconsin

45 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Wisconsin.

Ciudades en Wisconsin

Texto oficial del estudio (inglés)

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  • Circuit Clinical/SSM Health Dean Medical Group ( Site 0129), Madison
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT06345729

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  • Duluth Clinic Ashland, Ashland
  • Bellin Memorial Hospital, Green Bay
  • Froedtert Menomonee Falls Hospital, Menomonee Falls
  • y 5 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT07388524

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
  • ThedaCare Regional Cancer Center, Appleton
  • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton, Appleton
  • y 52 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  • Duluth Clinic Ashland, Ashland
  • Northwest Wisconsin Cancer Center, Ashland
  • Essentia Health-Hayward Clinic, Hayward
  • y 2 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Wisconsin Carbone Cancer Center, Madison
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #33, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT05176483

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
  • Duluth Clinic Ashland, Ashland
  • Marshfield Medical Center-EC Cancer Center, Eau Claire
  • y 18 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06498635

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  • Wisconsin Institute for Medical Research, Madison
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06625775

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  • HSHS St. Vincent Hospital Regional Cancer Center, Green Bay
  • Local Institution - 0421, Marshfield
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07361510

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT05877599

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  • Research Site, Schofield
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06868277

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Minnesota Oncology Hematology, P.A., Hudson
  • Froedtert Hospital/Medical College of Wisconsin, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07222566

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  • Research Site, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06218914

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Aurora Cancer Care-Grafton, Grafton
  • Aurora BayCare Medical Center, Green Bay
  • Aurora St. Luke's Medical Center, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06758401

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • Aurora Cancer Care-Southern Lakes VLCC, Burlington
  • Marshfield Clinic-Chippewa Center, Chippewa Falls
  • Aurora Saint Luke's South Shore, Cudahy
  • y 27 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • University Hospital and UW Health Clinics, Madison
  • Medical College of Wisconsin, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06890598

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Gundersen Lutheran Medical Center, La Crosse
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06712316

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  • UW Health Carbone Cancer Center, Madison
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07488676

HEARTS Trial for Thoracic Cancers

  • University of Wisconsin - Madison, Madison
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07132918

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • ThedaCare Regional Cancer Center, Appleton
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT05059444

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  • Froedtert Hospital - Clinical Cancer Center, Milwaukee
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06914128

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

  • Medical College of Wisconsin, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06561685

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical, Madison
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06119581

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • Ascension Network - St Elizabeth's Hospital, Appleton
  • Ascension Columbia St. Mary's, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06793215

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, Eau Claire
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07291037

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  • The Board of Regents of the University of Wisconsin, Madison
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07070232

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • Research Site, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 ago 2026 · NCT06350097

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

  • University of Wisconsin - Carbone Cancer Center, Madison
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06586515

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • University of Wisconsin- Madison, Madison
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT05592626

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

  • Northwest Wisconsin Cancer Center, Ashland
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 jul 2026 · NCT06686771

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

  • University of Wisconsin (Carbone Cancer Center), Madison
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 jun 2026 · NCT06026410

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Langlade Hospital and Cancer Center, Antigo
  • Duluth Clinic Ashland, Ashland
  • Aurora Cancer Care-Southern Lakes VLCC, Burlington
  • y 27 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 jun 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • Duluth Clinic Ashland, Ashland
  • Aurora Cancer Care-Southern Lakes VLCC, Burlington
  • Aurora Saint Luke's South Shore, Cudahy
  • y 18 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 may 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Duluth Clinic Ashland, Ashland
  • Aurora Cancer Care-Southern Lakes VLCC, Burlington
  • Aurora Saint Luke's South Shore, Cudahy
  • y 26 más
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT06616584

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

  • Univeristy of Wisconsin, Madison
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04317534

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Duluth Clinic Ashland, Ashland
  • Marshfield Medical Center-EC Cancer Center, Eau Claire
  • Gundersen Lutheran Medical Center, La Crosse
  • y 5 más
ReclutandoFase 2
18 Minutes · Todos los sexos · Actualizado el 5 may 2026 · NCT06031688

De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.